| Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker (NCT05763511) | University of Aarhus | 2022-07-01 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer (NCT05451849) | TCR2 Therapeutics | 2022-06-21 |
| First-line Olaparib Combined With Bevacizumab Maintenance Therapy (NCT05440578) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-06-01 |
| Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer (NCT06883409) | Instituto Nacional de Cancerologia de Mexico | 2022-05-19 |
| A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C) (NCT06964165) | Tesaro, Inc. | 2022-04-14 |
| Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Real-world Clinical Setting (NCT05153603) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-04-01 |
| The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening (NCT05290961) | Chongqing University Cancer Hospital | 2022-03-09 |
| Retrospective Study of Brachytherapy (NCT05242861) | Zhejiang Cancer Hospital | 2022-02-20 |
| Treat of Functional Ovarian Cysts by Compare Between Cocs and Progesterone Only Pills (NCT05244811) | Sohag University | 2022-02-20 |
| A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors (NCT05194072) | Seagen, a wholly owned subsidiary of Pfizer | 2022-01-12 |
| IOTA Ultrasound Criteria and Serum CA 125 for Ovarian Malignancy Detection (NCT06977334) | Maharajgunj Medical Campus | 2022-01-01 |
| The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer (NCT05352217) | Stiftung Swiss Tumor Institute | 2021-12-13 |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing (NCT04981119) | A2 Biotherapeutics Inc. | 2021-10-29 |
| A Study of PF-07260437 in Advanced or Metastatic Solid Tumors (NCT05067972) | Pfizer | 2021-10-07 |
| A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) (NCT05001282) | Elucida Oncology | 2021-09-13 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer (NCT04807166) | Wenjun Cheng | 2021-08-24 |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) (NCT04956640) | Eli Lilly and Company | 2021-07-19 |
| Spectroscopy in Ovarian Cancer (NCT04817449) | University of Exeter | 2021-06-28 |
| A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer (NCT04999605) | Akeso | 2021-06-24 |
| A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors (NCT04895709) | Bristol-Myers Squibb | 2021-05-27 |
| Improved Diagnosis of Ovarian Cancer (NCT05842629) | University of Aarhus | 2021-05-15 |
| Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. (NCT05610501) | Universitaire Ziekenhuizen KU Leuven | 2021-05-01 |
| A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study (NCT04641247) | GlaxoSmithKline | 2021-04-16 |
| Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian Cancer (NCT04971421) | The Netherlands Cancer Institute | 2021-04-14 |
| Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer (NCT04519151) | Sheba Medical Center | 2021-04-12 |
| Study of AK112 in the Treatment of Advanced Gynecological Tumors (NCT04870177) | Akeso | 2021-04-09 |
| Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer (NCT04593381) | Gemelli Molise Hospital | 2021-03-01 |
| A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Participants (NCT04893551) | BerGenBio ASA | 2021-02-25 |
| CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929) | Carisma Therapeutics Inc | 2021-02-02 |
| A Study of SGN-STNV in Advanced Solid Tumors (NCT04665921) | Seagen Inc. | 2021-01-18 |
| Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer (NCT04556071) | Xiaoxiang Chen | 2020-11-06 |
| To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer (NCT04561817) | Icahn School of Medicine at Mount Sinai | 2020-10-01 |
| Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery (NCT04498117) | CanariaBio Inc. | 2020-08-25 |
| An INternational Frontline Ovarian Cancer Real World Management Study (NCT04460768) | AstraZeneca | 2020-06-27 |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors (NCT04389632) | Seagen, a wholly owned subsidiary of Pfizer | 2020-06-08 |
| Impact of the COVID-19 Pandemic in Gynecological Oncology (NCT04351139) | Hospices Civils de Lyon | 2020-05-06 |
| Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer (NCT04794322) | Massachusetts General Hospital | 2020-04-13 |
| Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly Diagnosed Advanced Ovarian Cancer Patients (NCT04222465) | AstraZeneca | 2020-03-19 |
| A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indications in South Korea (NCT04589039) | Takeda | 2020-03-16 |
| Diagnosing Ovarian Cysts - the DOC Study (NCT04188652) | Rigshospitalet, Denmark | 2020-01-01 |
| Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors. (NCT04283773) | Assiut University | 2019-12-24 |
| Cancer Loyalty Card Study (NCT03994653) | Imperial College London | 2019-11-04 |
| Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer (NCT03955471) | Tesaro, Inc. | 2019-10-03 |
| Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) (NCT04055038) | Blokhin's Russian Cancer Research Center | 2019-09-01 |
| Ovarium Cancer Detection by TEP's and ctDNA (NCT04022863) | Gynaecologisch Oncologisch Centrum Zuid | 2019-07-01 |
| Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study (NCT05734911) | Zhongda Hospital | 2019-01-01 |
| An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer (NCT01932125) | Hoffmann-La Roche | 2018-12-05 |
| A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer (NCT03574779) | Tesaro, Inc. | 2018-11-15 |
| A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer (NCT03602859) | Tesaro, Inc. | 2018-10-11 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) (NCT03648489) | Imperial College London | 2018-09-21 |
| Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy (NCT03593681) | Boston Scientific Corporation | 2018-08-27 |
| Gynacological Imaging Reporting and Data System in Ovarian Masses by Ultrasonography (NCT03175991) | Assiut University | 2018-07-05 |
| Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer (NCT03394885) | Duke University | 2018-06-19 |
| Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients (NCT03359850) | Tesaro, Inc. | 2018-02-20 |
| Pelvic Microbiomes of Benign and Malignant Ovarian Diseases (NCT03388996) | Lei Li | 2018-01-01 |
| A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy (NCT03326193) | Tesaro, Inc. | 2017-12-12 |
| Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovarian Cancer (NCT03858166) | Shandong University | 2017-12-01 |
| CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (NCT02900248) | CureOne | 2017-10-02 |
| Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer (NCT03371693) | Zhongnan Hospital | 2017-09-30 |
| EDMONd - Elemental Diet in Bowel Obstruction (NCT03150992) | Royal Surrey County Hospital NHS Foundation Trust | 2017-07-19 |
| Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib (NCT03314740) | Mario Negri Institute for Pharmacological Research | 2017-06-12 |
| Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers (NCT03112733) | Ilker Kahramanoglu | 2017-04-04 |
| Survival Outcomes of Ovarian Malignancies in Chinese Population (NCT03291262) | Lei Li | 2017-01-01 |
| Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer (NCT02659384) | European Organisation for Research and Treatment of Cancer - EORTC | 2016-12-23 |
| Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer. (NCT02903771) | Kazia Therapeutics Limited | 2016-12-05 |
| Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors (NCT02227654) | Frederick R. Ueland, M.D. | 2016-09-12 |
| A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations (NCT02950064) | Placon Therapeutics | 2016-09-01 |
| Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass. (NCT02785731) | Angle plc | 2016-07-14 |
| Intra-peritoneal Chemotherapy in Ovarian Cancer (NCT02861872) | Radboud University Medical Center | 2016-07-01 |
| Improving Quality of Care for Patients With Recurrent Ovarian Cancer (NCT02809339) | Radboud University Medical Center | 2016-07-01 |
| Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass. (NCT02781272) | Angle plc | 2016-06-30 |
| Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer (NCT02751918) | Bayer | 2016-06-08 |
| Ovarian Cancer Hemoscope Trial (NCT02811224) | Scripps Translational Science Institute | 2016-05-01 |
| Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (NCT02658214) | AstraZeneca | 2016-04-28 |
| A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. (NCT02711345) | Novartis Pharmaceuticals | 2016-04-15 |
| Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients (NCT02903004) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2016-04-11 |
| The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer (NCT02687321) | Brno University Hospital | 2016-04-01 |
| Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (MK-3475-100/KEYNOTE-100) (NCT02674061) | Merck Sharp & Dohme LLC | 2016-02-25 |
| Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy (NCT02786524) | University of Michigan | 2016-02-15 |
| Use of Regorafenib in Recurrent Epithelial Ovarian Cancer (NCT02736305) | National Cancer Centre, Singapore | 2016-02-03 |
| Sentinel Node Detection in Ovarian Cancer (NCT02540551) | Maastricht University Medical Center | 2016-01-01 |
| The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research (NCT02569983) | University of Birmingham | 2015-09-01 |
| Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer (NCT02524808) | Fundación de investigación HM | 2015-08-01 |
| Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers (NCT02487095) | National Cancer Institute (NCI) | 2015-07-30 |
| Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer (NCT02494791) | University Health Network, Toronto | 2015-07-01 |
| DNA Single Nucleotide Polymorphisms as Predictors of Toxicity (NCT02478476) | OvaGene Oncology, Inc. | 2015-07-01 |
| Biobehavioral Intervention in Gynecologic Oncology Patients (NCT02454036) | Rachel Miller | 2015-06-01 |
| AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites (NCT02417753) | National Cancer Institute (NCI) | 2015-04-03 |
| TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors (NCT02429700) | Beihua Kong | 2015-04-01 |
| TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors (NCT02429687) | Beihua Kong | 2015-04-01 |
| MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study (NCT02334371) | Maastricht University Medical Center | 2015-04-01 |
| A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (NCT02354586) | Tesaro, Inc. | 2015-03-23 |
| A Trial of Vigil for Participants With Ovarian Cancer (NCT02346747) | Gradalis, Inc. | 2015-02-01 |
| Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms (NCT05553067) | Sohag University | 2015-01-01 |
| The Canadian/US Integrative Oncology Study (NCT02494037) | The Canadian College of Naturopathic Medicine | 2015-01-01 |
| Venous Thromboembolic Complications in Ovarian Cancer (NCT02480790) | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | 2014-11-01 |
| Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study (NCT03270995) | McGill University | 2014-10-01 |
| Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer (NCT02243059) | Maastricht University Medical Center | 2014-09-01 |
| PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer (NCT02055690) | The Christie NHS Foundation Trust | 2014-09-01 |
| STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Cancer (NCT02676726) | Hospital Universitari Vall d'Hebron Research Institute | 2014-07-01 |